Prof Wiedermann - January presentation in SF, page-25

Personally I think if Herr-Vaxx shows good efficacy signs in the phase 1b results then a deal/takeover will follow.

The pipeline, ip and disruptive potential value of imu is too great for big pharma to ignore imho. Not only will the big companies want it, but also stop others from getting it.

To avoid a bidding war a good deal/takeover price would be required, more than double what vla went for imho.

But first we need to show some good signs in our phase 1b. Only 9 more trading days I'm guessing.